Steffen Flindt Nielsen @nicenielsen.bsky.social · 04/06/2026New secondary analysis from FLOW: losing weight and also not dying leads to improvemens in quality of life. This is truly a late breaking result… also the sky is still blue #nephsky #ERA26 000
Steffen Flindt Nielsen @nicenielsen.bsky.social · 04/06/2026Another negative trial in advanced CKD. Low dose rivaroxiban did not decrease CV risk in patients w CKD4-5 and high risk of CVD but the study was terminated early due to higher rates of major bleeding. Seems like a well done study. jamanetwork.com/journals/jam... #ERA26 #nephsky 110
Steffen Flindt Nielsen @nicenielsen.bsky.social · 04/06/2026Targeting NO in CKD? In ALPINE1 nurandociguat, which stimulates cGMP, leads to a significant but modest reduction in UACR in CKD w/wo DM2. This is on top of pretty good standard of care w. 70% sglt2i. But many did not high dose treatment. Will be interesting to follow #nephsky #ERA26 #ckd 000
Reposted by Steffen Flindt NielsenLars Mølgaard Saxhaug @load-dependent.eurosky.social · 12/03/2026The end of the road for rivaroxaban? Shows how important direct comparative trials among drugs within the same pharmacologic class are. #emimcc #cardiosky www.nejm.org/doi/full/10.... 6328
Reposted by Steffen Flindt NielsenSwapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/03/2026Finally, FINEONE shows Finerenone reduces albuminuria in T1DM www.nejm.org/doi/full/10.... @nejm.org #NephSKy 13113
Steffen Flindt Nielsen @nicenielsen.bsky.social · 20/02/2026I like this as a mechanistic article examining why #SGLT2i’s work, but I don’t agree that renal fractional reserve can be used to identify patients most likely to benefit from SGLT2i since I think almost everybody with DM2 would benefit from SGLT2i #nephsky academic.oup.com/ndt/advance-...academic.oup.comRenal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trialsAbstractBackground and hypothesis. Glomerular hyperfiltration is common in type 2 diabetes (T2D) and may reflect reduced nephron number and/or perturbed in 020
Steffen Flindt Nielsen @nicenielsen.bsky.social · 10/02/2026Glad to have contributed to this study, which has a very relevant clinical point: the BP lowering effect of SGLT2i of 4-5 mmHg is independent of renal function #nephsky #sglt2i 031
Reposted by Steffen Flindt NielsenKidney International @kidneyint.bsky.social · 29/01/2026Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q doi.org/10.1016/j.kint.2026.01.003 #OpenAccess #NephSky #MedSky #inflammation #pyelonephritis 011
Steffen Flindt Nielsen @nicenielsen.bsky.social · 16/12/2025Still interested in the mechanisms of #SGLT2i? I did a video with #Vumedi going through our study on the effects of empagliflozin on fluid and electrolyte balance. check it out: www.vumedi.com/video/fluid-... Link for the studies 👇 #medsky #nephskyvumedi.comFluid Balance in CKD: Empagliflozin Findings from SiRENAA video from William Shaffer (as part of ASN Kidney Week Highlights), posted on Nov 26, 2025. 111
Steffen Flindt Nielsen @nicenielsen.bsky.social · 30/11/2025Getting an early start on this years christmas decorations. My wife won’t let me put it up at home, so I guess I’ll bring it to work. #Nephsky #medsky 020
Reposted by Steffen Flindt NielsenIain Bressendorff, MD PhD @ibressendorff.bsky.social · 09/11/2025I think everyone is rightly sceptical if the large effect size, but given the high risk CVD risk and low cost/risk with fish oil, I feel it is too reactionary to just say “we need more trials”. We always need more trials, but they’re not likely to be forthcoming any time soon. #NephSky 242
Reposted by Steffen Flindt NielsenEvan Zeitler @littlebiggloms.bsky.social · 07/11/2025REMODEL is fantastic demonstration of what we can do with collaborative effort to perform what Kathy Tuttle calls mechanistic clinical trials! Semaglutide provides kidney protection via improvements in inflammation and microvascular function. Lots of data to parse going forward. #KidneyWk 194
Steffen Flindt Nielsen @nicenielsen.bsky.social · 09/11/2025Nothing works in dialysis - except fis oil. Truly amazing data from the PISCES. Should we begin perscribimg fish oil supplements to all our dialysis patients? In spite of my somewhat sceptical priors, I think the answer should be “yes” #NephSky #KidneyWk #nephrology 193
Steffen Flindt Nielsen @nicenielsen.bsky.social · 31/08/2025Check out our new paper! SGLT2i lower BP and the effect seems to be independent of baseline kidney function. A clinically relevant point, and something to take in to consideration when prescribing. #NephSky #MedSky #Hypertension #SGLT2i 062
Reposted by Steffen Flindt NielsenAmerican Journal of Hypertension @amjhypertension.bsky.social · 30/08/2025#WeekendReads from the #AdvanceAccess section Is the FLozin-BP effect modified by baseline GFR? An SR/MA 🔗 academic.oup.com/ajh/advance-... 🔒 #Hypertension #NephSky 033
